Clinical Trials
4 trialsNCT05756166 2025-06-24
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT04081389 2023-09-11
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
Roswell Park Cancer Institute
Phase 1 Completed
NCT03599453 2023-07-18
Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer
Roswell Park Cancer Institute
Phase EARLY_PHASE1 Completed
NCT01355393 2020-02-10
Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer
University of Washington
Phase 1/2 Completed